124.920USD+124.920盤後交易 (美東)
關鍵數據
127.260今開
127.510最高
1.24M成交量
--本益比TTM
0.00本益比動
--股利TTM
--換手率
124.330昨收
120.620最低
82.13M成交額
--本益比靜
--市淨率
0.00%股息率 TTM
--ROA
148.83052週最高
1.17量比
--淨利潤
--總股本
--每股盈餘TTM
--Beta
--ROE
5.69052週最低
5.54%振幅
--毛利率
0.00總市值
-4.50回報/風險
3.12%風險率
Abivax SA新聞
即將為您帶來更多新聞,敬請期待。 。 。
收益預測
Ionis Pharmaceuticals Inc
IONS
25
技術指標
Abivax SA簡介
Abivax SA is a clinical stage biopharmaceutical company focusing on the discovery, development and commercialization of anti-viral compounds and therapeutic vaccines against severe and life threatening infectious diseases. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The Company's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.
公司代碼ABVX
公司Abivax SA
CEOde Garidel (Marc)
網址https://www.abivax.com/
公司股東
常見問題
Abivax SA(ABVX)的當前股價是多少?
Abivax SA(ABVX)的當前股價是 124.32。
Abivax SA股票的52週最高點是148.83。
現在Abivax SA(ABVX)的股票是買入、持有還是賣出?
根據分析師評級,Abivax SA(ABVX)的總體評級為買入,目標價格為156.15。